Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Effect of DFATs implantation on the inhibition of atrophy in the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

The activity of platelet P2Y1, but not of P2X1 or P2Y12 receptor, continually decreases in citrated WB. by Juergen Koessler (847843)

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”

Kcnk5b requires CaMKK for growth and SHH/<i>shha</i> expression. by Xiaowen Jiang (8291814)

Schematic of the D2 model (standard non-competitive model). by Hidetoshi Urakubo (578508)

Comparison of potential energy minimization curves of hypothetical monomer chains from non-capsid and capsid dimers. by Weimin Wu (505435)

“…<p>Compared are apo 3KXS (A) and liganded 5E0I (B) non-capsid chains with the apo T = 4 1QGT capsid chains (C). …”

MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

Down-regulation of BjsR4 under tellurite and iron stresses, and impact of this down-regulation on survival at high iron concentration. by Julia Hahn (3279486)

“…<p><b>A)</b> The steady-state level of BjsR4 is decreased upon addition of tellurite. …”

hsa-let-7e-5p acts as a downstream mediator of circ_0000006 and circ_0000160. by Yong Liu (6908)

Structural details for each point mutation studied by X-ray crystallography in this study. by Aleksi Sutinen (10039145)

Subjects:

13 thaxtomin A-resistant mutants were isolated from a screen of 10⁷ mutants. by Chloe Casey (14341756)